DARING TO DREAM: TARGETING LIPOPROTEIN(A) AS A CAUSAL AND RISK-ENHANCING FACTOR



Glutamatergic dysfunction in Schizophrenia

Abstract The NMDA-R hypofunction model of schizophrenia started with the clinical observation of the precipitation of psychotic symptoms in patients with schizophrenia exposed to PCP or ketamine.Healthy volunteers exposed to acute low doses of ketamine experienced mild psychosis but also negative and cognitive type symptoms reminiscent of the full

read more